Product Details
| Product Name:
R916562 |
CAS No.:
1037798-41-6 |
| Supply Ability:
10g |
Release date:
2026/04/21 |
Product Introduction
Bioactivity
| Name | R916562 |
| Description | R916562 is an orally active, selective Axl/VEGF-R2 inhibitor with IC50 values of 136 nM and 24 nM, respectively, demonstrating anti-angiogenesis and anti-metastasis properties. |
| In vivo | Treatment with R916562 at dosages of 85 mg/kg or 125 mg/kg (administered orally twice daily for 21 days) leads to statistically significant tumor growth inhibitions of 69% and 83%, respectively. Additionally, R916562 achieves a 73% reduction in fibroblast growth factor-induced neovascularization in the mouse corneal micropocket assay at 100 mg/kg, and a 50% reduction at 50 mg/kg[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | VEGF-R2 | TAMReceptor | TAM Receptor | R-916562 | R916562 | R 916562 | Axl |
| Inhibitors Related | Ribociclib | Bemcentinib | Gilteritinib | Sorafenib | glycine | Nintedanib esylate | Regorafenib | Chloramphenicol | Thymoquinone | Lenvatinib | Pazopanib | Albendazole |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$2500.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-22 |
United States